KCNB1 and ischemic stroke: Designing a selective blocker for these mutated forms of Kv2.1 was shown to reduce ischemic stroke damage in the animal study, without adverse effect on Kv2.1 WT in healthy tissues, as a highly promising neuroprotective strategy [178].